Bellerophon Therapeutics (BLPH) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. The firm currently has $0.75 target price on the biotechnology company’s stock.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Several other equities analysts have also commented on the stock. Maxim Group set a $3.00 price objective on shares of Bellerophon Therapeutics and gave the stock a buy rating in a report on Monday, April 8th. HC Wainwright restated a buy rating and issued a $3.00 price objective on shares of Bellerophon Therapeutics in a report on Tuesday, January 29th.

Shares of BLPH stock opened at $0.67 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.99 and a current ratio of 2.99. Bellerophon Therapeutics has a one year low of $0.47 and a one year high of $3.30.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.11. As a group, equities analysts predict that Bellerophon Therapeutics will post -0.21 earnings per share for the current year.

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC lifted its holdings in shares of Bellerophon Therapeutics by 60.2% in the 4th quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 13,799 shares during the last quarter. Vanguard Group Inc increased its stake in Bellerophon Therapeutics by 2.5% during the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock worth $1,105,000 after buying an additional 25,300 shares during the period. Geode Capital Management LLC increased its stake in Bellerophon Therapeutics by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock worth $186,000 after buying an additional 27,027 shares during the period. Renaissance Technologies LLC increased its stake in Bellerophon Therapeutics by 4.7% during the 3rd quarter. Renaissance Technologies LLC now owns 1,213,276 shares of the biotechnology company’s stock worth $1,310,000 after buying an additional 54,076 shares during the period. Finally, Sabby Management LLC purchased a new stake in Bellerophon Therapeutics during the 1st quarter worth approximately $202,000. Hedge funds and other institutional investors own 47.60% of the company’s stock.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Recommended Story: What are gap-up stocks?

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.